Actively Recruiting
Evaluating Stapokibart Injections Effectiveness and Safety in Adolescents with Seasonal Allergic Rhinitis Receiving Background Therapy
Led by Chengdu Kangnuoxing Biopharma,Inc. · Updated on 2026-09-03
136
Participants Needed
27
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of stapokibart, a subcutaneous injection, in adolescent patients aged 12 to under 18 years with seasonal allergic rhinitis SAR. This randomized, double-blind, placebo-controlled phase III study also examines quality of life, pharmacokinetics, pharmacodynamics, and immunogenicity in participants receiving background therapy. Participants will receive either stapokibart or a placebo injection as an add-on to their standard care. The treatment is administered subcutaneously, and the study compares these two groups in parallel. All participants continue their usual medications for SAR throughout the study. During the trial, participants will undergo symptom scoring for nasal and ocular symptoms, quality of life questionnaires, blood tests for drug concentration and immune markers, and monitoring for adverse events. The main outcome is the change in nasal symptom scores over two weeks of treatment, with additional assessments extending to four and twelve weeks. The total study duration includes treatment and follow-up periods up to 12 weeks.
CONDITIONS
Brief Title
Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis
Research Team
Q
Qian Jia
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here